
Search Clinical Trials
Study is registered in ResearchMatch ![]() Sponsor Condition of Interest |
---|
Metabolic Syndrome and Fall Risk
![]()
VA Office of Research and Development
Metabolic Syndrome
Autonomic Neuropathy
Obesity and the metabolic syndrome (MetS) are rapidly growing problems. Individuals with the
MetS are at risk for not only future chronic diseases, but they have a higher prevalence of
neuropathy, including cardiac autonomic neuropathy, and have a higher incidence of falls.... expand
Obesity and the metabolic syndrome (MetS) are rapidly growing problems. Individuals with the MetS are at risk for not only future chronic diseases, but they have a higher prevalence of neuropathy, including cardiac autonomic neuropathy, and have a higher incidence of falls. Currently there are no effective therapies to prevent or reverse the neuropathy seen in the MetS or to reduced the fall risk in this population. This research project will determine if a tailored balance exercise program will have functional benefits and result in a reduced fall risk in the growing population of patients with the MetS and neuropathy. Type: Interventional Start Date: Jan 2017 |
Exercise Plus Duloxetine for Knee Osteoarthritis and Depression
![]()
University of Maryland, Baltimore
Knee Osteoarthritis
Depression
This study evaluates the addition of duloxetine to aerobic exercise in the treatment of
symptomatic knee osteoarthritis and depressive symptoms in adults. All participants will
receive the receive the treatment protocol, which will first be evaluated in terms of
feasibility... expand
This study evaluates the addition of duloxetine to aerobic exercise in the treatment of symptomatic knee osteoarthritis and depressive symptoms in adults. All participants will receive the receive the treatment protocol, which will first be evaluated in terms of feasibility and then pilot tested. Type: Interventional Start Date: Oct 2021 |
Robot Aided Rehabilitation - Multi-joint Evaluations
![]()
University of Maryland, Baltimore
Stroke
Sensory and motor impairments following stroke can lead to substantial disability involving
the arm and hand. The investigator hypothesized that excessive local and cross-coupled
stiffness, diminished individuation and proprioceptive acuity will be present among multiple
degree... expand
Sensory and motor impairments following stroke can lead to substantial disability involving the arm and hand. The investigator hypothesized that excessive local and cross-coupled stiffness, diminished individuation and proprioceptive acuity will be present among multiple degree of freedom in the upper limb. The stiffness and spasticity will increase with time post-stroke. The objective of this study is to quantify the progression throughout the arm and hand during recovery from stroke. The investigator will measure the clinical assessment scores, and neuromechanical properties including range of motion, active and passive cross coupling, and spasticity by the IntelliArm robot. Type: Observational Start Date: May 2018 |
Hyperbaric Oxygen Brain Injury Treatment Trial
![]()
Hennepin Healthcare Research Institute
Traumatic Brain Injury
The purpose of this innovative adaptive phase II trial design is to determine the optimal
combination of hyperbaric oxygen treatment parameters that is most likely to demonstrate
improvement in the outcome of severe TBI patients in a subsequent phase III trial.
expand
The purpose of this innovative adaptive phase II trial design is to determine the optimal combination of hyperbaric oxygen treatment parameters that is most likely to demonstrate improvement in the outcome of severe TBI patients in a subsequent phase III trial. Type: Interventional Start Date: Jun 2018 |
OASIS-HAE: A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 721744 or IONIS-PKK-LRx)...
Ionis Pharmaceuticals, Inc.
Hereditary Angioedema
The purpose of this study is to evaluate the safety and efficacy of donidalorsen in
participants with HAE and effect of donidalorsenon the quality and pattern of HAE attacks and
their impact on quality of life (QoL).
expand
The purpose of this study is to evaluate the safety and efficacy of donidalorsen in participants with HAE and effect of donidalorsenon the quality and pattern of HAE attacks and their impact on quality of life (QoL). Type: Interventional Start Date: Dec 2021 |
Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease...
Merck Sharp & Dohme LLC
End-Stage Renal Disease
End-Stage Kidney Disease
Kidney Failure, Chronic
The purpose of this study is to evaluate the efficacy and safety of two different doses of
MK-2060 (a monoclonal antibody against Factor XI) in end stage renal disease (ESRD)
participants receiving hemodialysis via an arteriovenous graft (AVG). Data from this study
will be... expand
The purpose of this study is to evaluate the efficacy and safety of two different doses of MK-2060 (a monoclonal antibody against Factor XI) in end stage renal disease (ESRD) participants receiving hemodialysis via an arteriovenous graft (AVG). Data from this study will be used to aid dose selection of MK-2060 in future studies. The primary hypothesis is that at least one of the MK-2060 doses is superior to placebo in increasing the time to first occurrence of AVG event. Type: Interventional Start Date: Sep 2021 |
Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia
Janssen Research & Development, LLC
Warm Autoimmune Hemolytic Anemia
The main purpose of this study is to evaluate the efficacy and safety of M281 in participants
with warm autoimmune hemolytic anemia (wAIHA).
expand
The main purpose of this study is to evaluate the efficacy and safety of M281 in participants with warm autoimmune hemolytic anemia (wAIHA). Type: Interventional Start Date: Oct 2019 |
RejuvenAir® System Trial for COPD With Chronic Bronchitis
CSA Medical, Inc.
Chronic Bronchitis
Chronic Obstructive Pulmonary Disease (COPD) is defined as an impaired ability to move air
within the lungs and is a major public health problem that is projected to rank fifth
worldwide in terms of disease burden and third in terms of mortality. Chronic bronchitis (CB)
is... expand
Chronic Obstructive Pulmonary Disease (COPD) is defined as an impaired ability to move air within the lungs and is a major public health problem that is projected to rank fifth worldwide in terms of disease burden and third in terms of mortality. Chronic bronchitis (CB) is a common clinical phenotype within the umbrella of a COPD diagnosis and is classically defined as chronic cough and sputum production for 3 months a year for 2 consecutive years2, but many studies have used different definitions to define it- chronic cough and sputum production for one year or cough and sputum production on most days of the week. CB is associated with multiple clinical consequences, including; the worsening of lung function decline, increasing risk of acute exacerbations of COPD, increased risk of developing pneumonia, reduced health related quality of life, and an increase in all-cause mortality. Type: Interventional Start Date: Jul 2020 |
Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine
Amgen
Migraine
This study will evaluate the efficacy and safety of erenumab in migraine prevention in
children (6 to <12 years) and adolescents (12 to <18 years) with chronic migraine. The study
hypothesis is that in pediatric subjects with chronic migraine, the combined erenumab dose
group... expand
This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to <12 years) and adolescents (12 to <18 years) with chronic migraine. The study hypothesis is that in pediatric subjects with chronic migraine, the combined erenumab dose group has a greater reduction from baseline to week 9 through week 12 (month 3) in monthly migraine days (MMDs) when compared with placebo in the double-blind treatment phase (DBTP). Type: Interventional Start Date: Sep 2019 |
Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve...
Abbott Medical Devices
Mitral Regurgitation
Mitral Insufficiency
Mitral Valve Insufficiency
Cardiovascular Diseases
Valve Disease, Heart
Prospective, controlled, multicenter clinical investigation with three trial cohorts:
Randomized, Non-repairable, and Severe Mitral Annular Calcification (MAC). Subjects in the
Randomized cohort will be randomized in a 1:1 ratio to the trial device or to the MitraClip
system.... expand
Prospective, controlled, multicenter clinical investigation with three trial cohorts: Randomized, Non-repairable, and Severe Mitral Annular Calcification (MAC). Subjects in the Randomized cohort will be randomized in a 1:1 ratio to the trial device or to the MitraClip system. Subjects in the Non-repairable and Severe MAC cohorts will receive the trial device. The objective of the Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation (SUMMIT) is to evaluate the safety and effectiveness of the Tendyne Transcatheter Mitral Valve System for the treatment of patients with symptomatic, moderate-to-severe or severe mitral regurgitation or for patients with symptomatic mitral valve disease due to severe mitral annular calcification. This randomized controlled trial will provide the opportunity to evaluate the safety and clinical benefits of the Tendyne Transcatheter Mitral Valve System compared to the MitraClip System in patients with symptomatic, moderate-to-severe or severe mitral regurgitation, within approved MitraClip indications. In addition, the safety and effectiveness of the Tendyne Transcatheter Mitral Valve System will be evaluated in patients with severe mitral annular calcification who are at prohibitive risk for mitral valve surgery. Patients who are not suitable for mitral valve surgery for reasons other than severe mitral annular calcification and are also not suitable for transcatheter repair with MitraClip, will be enrolled in the Non-repairable cohort. Subjects will be seen at screening, pre- and post-procedure, discharge, 30 days, 3 months, 6 months, and annually through 5 years. Type: Interventional Start Date: Jun 2018 |
Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial
Thomas G. Brott, M.D.
Carotid Stenosis
Carotid revascularization for primary prevention of stroke (CREST-2) is two independent
multicenter, randomized controlled trials of carotid revascularization and intensive medical
management versus medical management alone in patients with asymptomatic high-grade carotid... expand
Carotid revascularization for primary prevention of stroke (CREST-2) is two independent multicenter, randomized controlled trials of carotid revascularization and intensive medical management versus medical management alone in patients with asymptomatic high-grade carotid stenosis. One trial will randomize patients in a 1:1 ratio to endarterectomy versus no endarterectomy and another will randomize patients in a 1:1 ratio to carotid stenting with embolic protection versus no stenting. Medical management will be uniform for all randomized treatment groups and will be centrally directed. Type: Interventional Start Date: Dec 2014 |
Peer Activate: Trial of Peer-Delivered Behavioral Activation for Methadone Adherence
University of Maryland, College Park
Substance-Related Disorders
Opioid Medication Assisted Treatment
Opioid Use Disorder
Opioid Use
Opioid Addiction
The purpose of this study is to evaluate the feasibility and effectiveness of a peer-led,
brief, behavioral intervention to improve adherence to medication for opioid use disorder
(MOUD) among low-income, minority individuals living with opioid use disorder (OUD) in
Baltimore,... expand
The purpose of this study is to evaluate the feasibility and effectiveness of a peer-led, brief, behavioral intervention to improve adherence to medication for opioid use disorder (MOUD) among low-income, minority individuals living with opioid use disorder (OUD) in Baltimore, Maryland. The intervention is based on behavioral activation (BA) and is specifically designed to be implemented by a trained peer recovery specialist. In this Type 1 hybrid effectiveness-implementation randomized controlled trial (RCT), we will evaluate the effectiveness and implementation of Peer Activate vs. treatment as usual (TAU) over six months. Type: Interventional Start Date: Apr 2022 |
A Study of FT-7051 in Men With MCRPC
Forma Therapeutics, Inc.
Metastatic Castration-resistant Prostate Cancer
This is a Phase 1, open-label study that will evaluate the safety and tolerability of FT-7051
and determine the recommended Phase 2 dose (RP2D) as well as pharmacokinetics (PK),
preliminary anti-tumor activity, and pharmacodynamics (PD) of FT-7051 in men with metastatic
castration-resistant... expand
This is a Phase 1, open-label study that will evaluate the safety and tolerability of FT-7051 and determine the recommended Phase 2 dose (RP2D) as well as pharmacokinetics (PK), preliminary anti-tumor activity, and pharmacodynamics (PD) of FT-7051 in men with metastatic castration-resistant prostate cancer who have progressed despite prior therapy and had been treated with at least one potent anti-androgen therapy. The starting dose, 25 mg once daily (QD), of FT-7051 administered discontinuously (21 days on/7 days off) in 28-day cycles. Type: Interventional Start Date: Dec 2020 |
The JenaValve ALIGN-AR Pivotal Trial
JenaValve Technology, Inc.
Aortic Regurgitation
Aortic Valve Insufficiency
Aortic Insufficiency
Aortic Valve Disease
To collect information about treatment for symptomatic severe Aortic Regurgitation (AR),
which affects the aortic valve in the heart. Aortic regurgitation is a condition where aortic
valve in the heart does not close tightly and allows some blood to leak back into the heart... expand
To collect information about treatment for symptomatic severe Aortic Regurgitation (AR), which affects the aortic valve in the heart. Aortic regurgitation is a condition where aortic valve in the heart does not close tightly and allows some blood to leak back into the heart chamber. Symptoms of aortic regurgitation may include fatigue and shortness of breath. The preferred treatment for severe aortic regurgitation is aortic valve replacement surgery. Type: Interventional Start Date: May 2020 |
Shigella CVD 30000: Study of Responses to Vaccination With Shigella Vaccine
University of Maryland, Baltimore
Shigella
The purpose of this study is to determine whether SF2a-TT15 (a monovalent synthetic
carbohydrate-based conjugate Shigella vaccine) is safe and effective in the prevention of
Shigella infection.
expand
The purpose of this study is to determine whether SF2a-TT15 (a monovalent synthetic carbohydrate-based conjugate Shigella vaccine) is safe and effective in the prevention of Shigella infection. Type: Interventional Start Date: Mar 2020 |
AFPᶜ³³²T in Advanced HCC
Adaptimmune
Hepatocellular Cancer
AFP Expressing Tumors
This first time in human study is intended for men and women between 18 and 75 years of age
who have advanced liver cancer which has grown or returned after being treated or another AFP
expressing tumor. Those who did not tolerate or refused other therapies may also participate.... expand
This first time in human study is intended for men and women between 18 and 75 years of age who have advanced liver cancer which has grown or returned after being treated or another AFP expressing tumor. Those who did not tolerate or refused other therapies may also participate. The purpose of this study is to test the safety of genetically changed T cells that target alpha-fetoprotein (AFP) and find out what effects, if any, they have in subjects with liver cancer or other AFP expressing tumor types. This study is for subjects who have a blood test positive for appropriate HLA-A*02 P Group and have adequate AFP protein in blood or tumor, and whose noncancerous liver tissue has very little AFP protein (Liver only). The study will take the subject's T cells, which are a natural type of immune cell in the blood, and send them to a laboratory to be modified. The changed T cells used in this study will be the subject's own T cells that have been genetically changed with the aim of attacking and destroying cancer cells. The manufacturing of T cells takes about 1 month to complete. The T cells will be given back to the subject through an intravenous infusion after 3 days of chemotherapy. The study will evaluate three different cell dose levels in order to find out the target cell dose. Once the target cell dose is determined, additional subjects will be enrolled to further test the safety and effects at this cell dose. Subjects will be hospitalized for at least 1 week after receiving their T cells back and then seen frequently by the Study Physician for the next 6 months. After that, subjects will be seen every three months. If subjects have disease progression or withdraw from the study, they will then be entered into a long-term follow up for safety monitoring. In long-term follow up, subjects will be seen every 6 months by their Study Physician for the first 5 years after the T cell infusion and annually for the next 10 years. Type: Interventional Start Date: May 2017 |
Gastroschisis Outcomes of Delivery (GOOD) Study
Medical College of Wisconsin
Gastroschisis
The objective of this study is to investigate the hypothesis that delivery at 35 0/7- 35 6/7
weeks in stable patients with gastroschisis is superior to observation and expectant
management with a goal of delivery at 38 0/7 - 38 6/7 weeks. To test this hypothesis, we will
complete... expand
The objective of this study is to investigate the hypothesis that delivery at 35 0/7- 35 6/7 weeks in stable patients with gastroschisis is superior to observation and expectant management with a goal of delivery at 38 0/7 - 38 6/7 weeks. To test this hypothesis, we will complete a randomized, prospective, multi-institutional trial across NAFTNet-affiliated institutions. Patients may be enrolled in the study any time prior to 33 weeks, but will be randomized at 33 weeks to delivery at 35 weeks or observation with a goal of 38 weeks. The primary composite outcome will include stillbirth, neonatal death prior to discharge, respiratory morbidity, and need for parenteral nutrition at 30 days. Type: Interventional Start Date: Feb 2018 |
Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid...
NGM Biopharmaceuticals, Inc
Mesothelioma
Glioblastoma
Renal Cell Carcinoma
Non Small Cell Lung Cancer
Melanoma
Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or
Metastatic Solid Tumor Malignancies
expand
Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies Type: Interventional Start Date: Jun 2021 |
Selective Avoidance of Nodal VolumEs at Minimal Risk (GCC 20110)
University of Maryland, Baltimore
Head and Neck Cancer
Oropharynx Cancer
Oropharyngeal Squamous Cell Carcinoma
This is a phase II, non-randomized, therapeutic trial with the primary objective to determine
the efficacy of reduced contralateral (C/L) elective nodal treatment volumes in preventing
C/L recurrences at 2 years in patients with p16 positive oropharyngeal squamous cell
carcinoma... expand
This is a phase II, non-randomized, therapeutic trial with the primary objective to determine the efficacy of reduced contralateral (C/L) elective nodal treatment volumes in preventing C/L recurrences at 2 years in patients with p16 positive oropharyngeal squamous cell carcinoma undergoing definitive or adjuvant RT. Type: Interventional Start Date: Mar 2021 |
The Effects of Fluoxetine and/or DHEA
University of Maryland, Baltimore
Type 1 Diabetes Mellitus
(1) To determine how the Selective Serotonin Reuptake Inhibitor (SSRI), fluoxetine (Prozac),
an antidepressant often used to treat depression, stimulates the participant's body's ability
to defend against low blood sugar (hypoglycemia). (2) To learn how a hormone,
dehydroepiandrosterone... expand
(1) To determine how the Selective Serotonin Reuptake Inhibitor (SSRI), fluoxetine (Prozac), an antidepressant often used to treat depression, stimulates the participant's body's ability to defend against low blood sugar (hypoglycemia). (2) To learn how a hormone, dehydroepiandrosterone (DHEA), stimulates the participant's body's ability to defend itself from low blood sugar (hypoglycemia). DHEA is a hormone produced naturally in the human body. However, it can be manufactured and is sold as an over-the-counter dietary supplement. The dose the investigators are giving in this study is higher than the usual recommended dosage taken as a supplement for certain medical conditions. (3) To study combined effects of fluoxetine and DHEA during low blood glucose. In the present study, the investigators will measure the participant's body's responses to hypoglycemia when given fluoxetine or DHEA or fluoxetine and DHEA or a placebo (a pill with no fluoxetine or DHEA). Approximately 64 individuals with type 1 diabetes will take part in this study. Type: Interventional Start Date: Dec 2017 |
The Utility of the Validated Intraoperative Bleeding Scale in Spine Surgery
University of Maryland, Baltimore
Intraoperative Blood Loss
Thoracolumbar Spine Surgery
This is a single-center, prospective, observational study that will compare the blood
transfusion rate between intraoperative bleeding severity characterized using the Validated
Intraoperative Bleeding Scale (VIBe).
expand
This is a single-center, prospective, observational study that will compare the blood transfusion rate between intraoperative bleeding severity characterized using the Validated Intraoperative Bleeding Scale (VIBe). Type: Observational Start Date: Mar 2022 |
Bringing Health Home
University of Maryland, Baltimore
Mental Disorders, Severe
Individuals suffering from Serious Mental Illnesses (SMI) are at risk for serious adverse
health and social outcomes compared to the general population due to a high prevalence of
chronic physical health disorders such as cardiovascular disease, hypertension, and Type II
Diabetes,... expand
Individuals suffering from Serious Mental Illnesses (SMI) are at risk for serious adverse health and social outcomes compared to the general population due to a high prevalence of chronic physical health disorders such as cardiovascular disease, hypertension, and Type II Diabetes, along with consequences of mental distress such as suicide, substance abuse, and acute stress.While pharmacological treatments exist for these conditions, they have limited effectiveness in SMI populations because: (1) up to 60% of individuals with SMI do not take their psychiatric or somatic medications as prescribed, (2) individuals with SMI have poorer clinical outcomes and experience high rates of hospitalizations, and (3) individuals with SMI experience worse care. Challenges in the management of these complex chronic health and mental health conditions have led to the development of intensive community-based service delivery programs. However, as currently structured these intensive in-person interventions have only had limited impact optimizing service delivery, and consequently on adherence to treatment and health outcomes. While in-person clinical contact in select situations is important, telehealth may serve as an effective and nimble intervention to help meet the high need for clinical intervention for SMI populations and particularly those with geographically limited-service access. Although research exists regarding the efficacy of telehealth with SMI populations, most of the existing interventions with this population have been designed for institutional settings, not community settings, because of barriers to adoption of telehealth such as limited access to digital technology, technical support difficulties and cost of necessary technology. The COVID-19 pandemic has underscored the need for developing effective telemedicine and telemonitoring technologies to serve the unique needs of this vulnerable population in community settings. This project builds on a successful Phase I SBIR project and ongoing Phase II clinical trial of the Medherent medication management platform. This study will test an expanded set of telehealth care-coordination services that can be used to address the broad health needs of individuals diagnosed with SMI living in community settings and supported by community mental health agencies. The study team will recruit 300 individuals, including 200 individuals currently using the device and 100 new users of the device. The study will test the existing Medherent platform and a set of extended services. Our key outcomes include acute service use, receipt of preventive and other health screenings, health outcomes and costs of services. The study will use a Stepped Wedge Design approach with a matched comparison group to identify potential benefits of the intervention. Type: Interventional Start Date: Apr 2022 |
GMCI Plus Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC
Candel Therapeutics, Inc.
Non Small Cell Lung Cancer
The purpose of this phase 2 multi-site trial is to evaluate the safety and efficacy of adding
Gene Mediated Cytotoxic Immunotherapy (GMCI™) to standard of care in patients with stage
III/IV NSCLC that are not responding to a first line immune checkpoint inhibitor (ICI). GMCI... expand
The purpose of this phase 2 multi-site trial is to evaluate the safety and efficacy of adding Gene Mediated Cytotoxic Immunotherapy (GMCI™) to standard of care in patients with stage III/IV NSCLC that are not responding to a first line immune checkpoint inhibitor (ICI). GMCI kills tumor cells and creates an immune stimulatory environment in the tumor. Killing tumor cells in an immune stimulatory environment induces the body's immune system to detect and destroy cancer cells. Patients will receive two courses of GMCI with aglatimagene besadenovec injected into an accessible involved tumor site followed by 14 days of oral valacyclovir. Patients will continue with standard of care ICI, plus chemotherapy if indicated. The hypothesis is that the combination of GMCI and ICI may improve the response rate and overall clinical long-term benefit for NSCLC patients. Type: Interventional Start Date: Oct 2020 |
Case-Control Study of the Glycotest™ HCC Panel vs AFP for the Detection of Early-stage Hepatocellular...
Glycotest, Inc.
Carcinoma, Hepatocellular
Cirrhosis, Liver
Clinical guidelines (AASLD) recommend the use of abdominal ultrasound (US) for surveillance
testing for the early detection of Hepatocellular Carcinoma (HCC). The serum protein
biomarker alpha-fetoprotein (AFP) is commonly used to augment US but its use alone is not
recommended... expand
Clinical guidelines (AASLD) recommend the use of abdominal ultrasound (US) for surveillance testing for the early detection of Hepatocellular Carcinoma (HCC). The serum protein biomarker alpha-fetoprotein (AFP) is commonly used to augment US but its use alone is not recommended by clinical guidelines. Despite evidence that HCC surveillance improves early detection and reduces mortality from HCC, current HCC surveillance tests lack sensitivity, leaving a significant proportion of patients to present with late-stage disease. The Glycotest HCC Panel has shown better sensitivity than AFP, which is ineffective for the detection of early-stage HCC. This clinical study seeks to validate the Glycotest HCC Panel using a large multicenter cohort of cases and controls that includes patients diagnosed with early-stage HCC against a background of cirrhosis and cirrhotic patients without HCC (at risk) undergoing an established surveillance protocol. Type: Observational Start Date: May 2019 |
Sleep for Stroke Management and Recovery Trial
University of Michigan
Ischemic Stroke
Sleep Apnea
Sleep Apnea, Obstructive
TIA
Stroke
The purpose of this study is to determine whether treatment of obstructive sleep apnea (OSA)
with positive airway pressure starting shortly after acute ischemic stroke or high risk TIA
(1) reduces recurrent stroke, acute coronary syndrome, and all-cause mortality 6 months after... expand
The purpose of this study is to determine whether treatment of obstructive sleep apnea (OSA) with positive airway pressure starting shortly after acute ischemic stroke or high risk TIA (1) reduces recurrent stroke, acute coronary syndrome, and all-cause mortality 6 months after the event, and (2) improves stroke outcomes at 3 months in patients who experienced an ischemic stroke. Type: Interventional Start Date: May 2019 |